FDA Grants Approval for Haloperidol ANDA214470 by Alembic
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
Company
Alembic Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
Why it matters
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
What changed
Regulatory Approval
Analysis
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 214470 for Haloperidol submitted by Alembic.
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
Monitor market entry timelines and pricing strategies from Alembic and competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.